Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Raolat M Abdulai, Mona Bafadhel, Ashish Bansal, Deborah Bauer, Surya P Bhatt, Stephanie A Christenson, Paula Dakin, Nicola A Hanania, Elizabeth Laws, Xin Lu, Jennifer Maloney, Alberto Papi, Klaus F Rabe, Lacey B Robinson, Dave Singh, Claus F Vogelmeier

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: England : Respiratory medicine , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 740493

 BACKGROUND: The body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index predicts 5-year mortality risk in chronic obstructive pulmonary disease (COPD)
  higher scores predict worse outcomes. Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4/13, reduced exacerbations and improved lung function in patients with COPD in phase 3 BOREAS trial (NCT03930732). We assessed dupilumab efficacy in patients with COPD and type 2 inflammation by baseline BODE index. METHODS: Patients with COPD, moderate-to-severe airflow limitation, screening blood eosinophils ≥300 cells/μL, and high exacerbation risk, on triple therapy, received 300-mg add-on dupilumab or placebo every 2 weeks for 52 weeks. Annualized moderate or severe COPD exacerbation rate and change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV RESULTS: Of 934 patients with reported baseline BODE index scores (dupilumab: 470
  placebo: 464), 61.8% had scores ≤4. Dupilumab reduced exacerbations versus placebo, regardless of baseline BODE index group. Exacerbation reductions were similar by BODE index group
  relative risk (95% confidence interval) for patients with BODE index >
 4 versus ≤4 was 0.656 (0.496-0.868) versus 0.718 (0.547-0.944). At Weeks 12 and 52, dupilumab consistently improved pre-bronchodilator FEV CONCLUSION: Dupilumab reduced exacerbations and improved lung function in patients with COPD and type 2 inflammation irrespective of baseline BODE index score. CLINICAL TRIAL REGISTRATION NUMBER: BOREAS trial NCT03930732.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH